Goldman Sachs upgrades 4507.JP, 4519.JP
Chugai Pharmaceutical files additional indication application for Tecentriq as maintenance therapy (¥7450.0000, 0)
FDA approves Lilly's EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis ($1144.68, 0.00)
Eli Lilly presents data on Foundayo at ADA 86th Scientific Sessions ($1131.42, 0.00)
Pharma Mar's Zepzelca approved by European Commission for the treatment of extensive-stage small cell lung cancer in combination with atezolizumab (€101.20, +1.20)
StreetAccount Summary - Trading higher/lower: Japan mid-day
BioMarin announces phase 3 pivotal study results for VOXZOGO (vosoritide) in children with hypochondroplasia met its primary endpoint ($50.20, 0.00)
Japan's MHLW approves Chugai's Alecensa for advanced or recurrent ALK fusion gene-positive solid tumors including pediatric patients (¥7885.0000, 0)
Japan's MHLW approves Chugai's FoundationOne CDx Cancer Genomic Profile as companion diagnostic for Alecensa for ALK fusion gene-positive solid tumors (¥7885.0000, 0)
Eli Lilly reports Surmount-maintain and Attain-maintain late-phase trials results, people with obesity maintained weight loss long term with either Foundayo or lower-dose Zepbound after switching from higher doses of injectable incretin therapy ($989.87, 0.00)
Powered by FactSet Research Systems Inc.